Creative Commons source reading · Alzheimer’s disease and related dementias
Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model.
Elizabeth Spangenberg; Paul L Severson; Lindsay A Hohsfield; Joshua Crapser; Jiazhong Zhang; Elizabeth A Burton; Ying Zhang; Wayne Spevak; Jack Lin; Nicole Y Phan; Gaston Habets; Andrey Rymar; Garson Tsang; Jason Walters; Marika Nespi; Parmveer Singh; Stephanie Broome; Prabha Ibrahim; Chao Zhang; Gideon Bollag; Brian L West; Kim N Green
Originally published in Nature communications · 2019-08-21
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Many risk genes for the development of Alzheimer's disease (AD) are exclusively or highly expressed in myeloid cells. Microglia are dependent on colony-stimulating factor 1 receptor (CSF1R) signaling for their survival. We designed and synthesized a highly selective brain-penetrant CSF1R inhibitor (PLX5622) allowing for extended and specific microglial elimination, preceding and during pathology development. We find that in the 5xFAD mouse model of AD, plaques fail to form in the parenchymal space following microglial depletion, except in areas containing surviving microglia. Instead, Aβ deposits in cortical blood vessels reminiscent of cerebral amyloid angiopathy. Altered gene expression in the 5xFAD hippocampus is also reversed by the absence of microglia. Transcriptional analyses of the residual plaque-forming microglia show they exhibit a disease-associated microglia profile. Collectively, we describe the structure, formulation, and efficacy of PLX5622, which allows for sustained microglial depletion and identify roles of microglia in initiating plaque pathogenesis.
Discussion
By way of mechanism for plaque seeding and growth, microglia could be: (1) secreting factors that facilitate Aβ fibrillization58, (2) physically forming plaque cores from extracellular Aβ via compaction59, or (3) ingesting, aggregating, and modifying extracellular Aβ internally, which is eventually released to seed plaques, in line with in vitro data60. Indeed, low concentrations of Aβ can be taken up by cells and concentrated into acidic vesicles, yielding favorable conditions for the spontaneous aggregation of Aβ15.
Editorial reading guide
- Was the evidence cross-sectional, longitudinal or experimental?
- How did the authors account for age, disease stage and differences among participants?
